If you’re asking which biosimilar manufacturers are preparing for Stelara (ustekinumab) patent expiry, here’s a practical snapshot and what to expect next.
What “patent expiry preparation” usually means for Stelara
- Stelara is protected by multiple patents (composition of matter, manufacturing methods, use) across different regions. Expiry dates vary by jurisdiction and by which patent dominates in a given market.
- Even after key patents expire, biosimilar products still face regulatory and commercial hurdles (regulatory approvals, potential patent litigations on secondary patents, and market access/price considerations).
- Companies don’t just file an application; they build manufacturing capacity, run analytical, PK/PD and immunogenicity comparability studies, and plan regulatory submissions and supply agreements.
Biosimilar players historically associated with ustekinumab
- Biocon and Mylan (now Viatris) have publicly disclosed collaboration to develop and commercialize an ustekinumab biosimilar in multiple markets.
- Other biosimilar developers in academia, contract manufacturing, or regional players have expressed interest or pursued development programs in various markets, but the public landscape is dynamic and jurisdiction-specific.
- It’s common for several companies to conduct early-stage development or seek partnerships even if regulatory approvals have not yet occurred in a given market.
What manufacturers typically do to prepare
- Secure development and commercialization rights in target markets.
- Invest in manufacturing scale-up and process development to ensure consistent, high-quality biosimilar production.
- Conduct bridging and comparability studies (analytical characterization, functional assays, PK/PD, immunogenicity) to demonstrate similarity to Stelara.
- Prepare regulatory submissions (BLA/MAA) and plan for potential regulatory pathways (including any region-specific requirements).
- Plan commercial strategies, including pricing, market access, and supply agreements with distributors and healthcare systems.
How to get the latest, country-specific details
- Patent expiry dates are jurisdiction-specific. To understand the exact expiry window for US/EU/other markets, you’ll want to consult:
- Patent landscapes for ustekinumab (USPTO, EPO, WIPO Patentscope)
- Regulatory agency databases (FDA Purple Book, EMA biosimilar information)
- Public company announcements and press releases from known developers
- If you tell me your target market(s), I can pull together a current, market-specific view of:
- Which patents are still in force and their expected expiry
- The list of confirmed ustekinumab biosimilar programs and any approved products in those markets
Would you like me to look up the latest country-by-country patent expiry timelines and which manufacturers have active ustekinumab biosimilar programs for your target market? If you specify a market (e.g., US, EU, India, etc.), I’ll tailor the info.